NZ596788A - Use of selected lactic acid bacteria for reducing infantile colic - Google Patents

Use of selected lactic acid bacteria for reducing infantile colic

Info

Publication number
NZ596788A
NZ596788A NZ596788A NZ59678807A NZ596788A NZ 596788 A NZ596788 A NZ 596788A NZ 596788 A NZ596788 A NZ 596788A NZ 59678807 A NZ59678807 A NZ 59678807A NZ 596788 A NZ596788 A NZ 596788A
Authority
NZ
New Zealand
Prior art keywords
lactic acid
acid bacteria
infantile colic
selected lactic
reducing
Prior art date
Application number
NZ596788A
Other languages
English (en)
Inventor
Eamonn Connolly
Bo Mollstam
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38790468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ596788(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of NZ596788A publication Critical patent/NZ596788A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NZ596788A 2006-06-05 2007-05-30 Use of selected lactic acid bacteria for reducing infantile colic NZ596788A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/446,628 US7374924B2 (en) 2006-06-05 2006-06-05 Use of selected lactic acid bacteria for reducing infantile colic
NZ572359A NZ572359A (en) 2006-06-05 2007-05-30 Use of selected lactic acid bacteria for reducing infantile colic

Publications (1)

Publication Number Publication Date
NZ596788A true NZ596788A (en) 2013-03-28

Family

ID=38790468

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ596788A NZ596788A (en) 2006-06-05 2007-05-30 Use of selected lactic acid bacteria for reducing infantile colic
NZ572359A NZ572359A (en) 2006-06-05 2007-05-30 Use of selected lactic acid bacteria for reducing infantile colic

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ572359A NZ572359A (en) 2006-06-05 2007-05-30 Use of selected lactic acid bacteria for reducing infantile colic

Country Status (20)

Country Link
US (3) US7374924B2 (enExample)
EP (1) EP2040722B1 (enExample)
JP (3) JP4520531B2 (enExample)
KR (2) KR101308865B1 (enExample)
CN (2) CN102488717B (enExample)
AU (2) AU2007200434B2 (enExample)
BR (1) BRPI0710944B8 (enExample)
CA (1) CA2650546C (enExample)
DK (1) DK2040722T3 (enExample)
GE (1) GEP20125480B (enExample)
HU (1) HUE026416T2 (enExample)
IL (1) IL194779A0 (enExample)
MX (1) MX2008014869A (enExample)
MY (1) MY162708A (enExample)
NZ (2) NZ596788A (enExample)
RU (1) RU2435844C2 (enExample)
SI (1) SI2040722T1 (enExample)
UA (1) UA93911C2 (enExample)
WO (1) WO2007142596A1 (enExample)
ZA (1) ZA200809531B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
EP2265135B1 (en) * 2008-03-14 2017-12-20 Nestec S.A. Synbiotic mixture
AU2014221272B2 (en) * 2008-11-03 2016-01-21 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
RU2517616C2 (ru) * 2008-11-03 2014-05-27 Нестек С.А. Питательная композиция, включающая пробиотики и улучшающая характер сна
US20110104327A1 (en) * 2009-04-23 2011-05-05 Bacterfield International S.A. Probiotic pet food
SG177541A1 (en) 2009-07-31 2012-02-28 Nestec Sa Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
NL2004101C2 (en) * 2010-01-15 2011-07-18 Friesland Brands Bv Ruminant il-10 and use in modulating immune response.
IT1401460B1 (it) * 2010-06-11 2013-07-26 Probiotical Spa "ceppi di batteri probiotici produttori di vitamina b12"
KR101706100B1 (ko) * 2011-12-15 2017-02-15 삼성전자주식회사 성형한계선도 획득용 시험장치
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
WO2015018883A2 (en) * 2013-08-09 2015-02-12 Ab-Biotics, S.A. Probiotic for infantile excessive crying
AU2015209763B2 (en) 2014-01-23 2020-12-24 Biogaia Ab Selection of agents modulating gastrointestinal pain
CN106794207A (zh) * 2014-10-29 2017-05-31 雀巢产品技术援助有限公司 使用罗伊氏乳杆菌在生命早期恢复微生物群生态失调
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
JP6529835B2 (ja) * 2015-06-23 2019-06-12 株式会社フィス 樹状細胞活性化剤
CN105219683B (zh) * 2015-11-04 2018-03-13 广东省农业科学院动物科学研究所 一株具有益生特征的罗伊氏乳杆菌菌株及其应用
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
CN106497840B (zh) * 2016-11-07 2019-06-21 江南大学 一种定向分离免疫调节性肠道乳杆菌的方法
CN117487686A (zh) * 2018-07-24 2024-02-02 生命大地女神有限公司 选择和使用褪黑素支持细菌以减少婴儿绞痛
MX2020014222A (es) * 2018-07-24 2021-03-09 Biogaia Ab Metodos terapeuticos que utilizan cepas bacterianas las cuales son capaces de aumentar los niveles de adenosina.
SG11202110355RA (en) * 2019-04-17 2021-11-29 Biogaia Ab Therapeutic microvesicles of probiotic bacteria
US20240165171A1 (en) * 2021-03-26 2024-05-23 Seoul National University R&Db Foundation Composition for enhancing physiological efficacy of lactic acid bacteria
CN117925484B (zh) * 2024-03-19 2024-07-09 山东中科嘉亿生物工程有限公司 一株改善睡眠呼吸暂停的罗伊氏粘液乳杆菌jylb-101及其产品和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518696A (en) 1983-01-11 1985-05-21 Chr. Hansen's Laboratory, Inc. Stabilized liquid bacterial suspension for oral administration to animals
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5534253A (en) 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
AU718040B2 (en) 1995-12-21 2000-04-06 Abbott Laboratories Use of lactobacillus reuteri to inhibit cryptosporidiosis in mammals
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US5800813A (en) 1996-11-12 1998-09-01 Biogaia Biologics Ab Treatment of cryptosporidium infections
KR19990024297A (ko) 1997-08-07 1999-04-06 오종석 인체 구강내 치태형성을 억제하는 신규한 유산균
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
EP1034788A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
EP1344458A1 (en) * 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
EP1567018B1 (en) * 2002-10-18 2009-07-01 Biogaia Ab Method of improving immune function in mammals using lactobacillus reuteri strains
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20040185032A1 (en) 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
EP1638414B1 (en) * 2003-06-23 2009-06-17 Nestec S.A. Infant or follow-on formula
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
US20060251634A1 (en) * 2005-05-06 2006-11-09 Ho-Jin Kang Method of improving immune function in mammals using lactobacillus strains with certain lipids
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic

Also Published As

Publication number Publication date
BRPI0710944A2 (pt) 2017-04-18
HUE026416T2 (en) 2016-07-28
SI2040722T1 (sl) 2016-02-29
AU2007200434A1 (en) 2007-12-20
EP2040722A4 (en) 2010-06-02
JP4520531B2 (ja) 2010-08-04
EP2040722B1 (en) 2015-11-11
RU2008147883A (ru) 2010-07-20
DK2040722T3 (en) 2016-02-01
US7374924B2 (en) 2008-05-20
RU2435844C2 (ru) 2011-12-10
JP2010202654A (ja) 2010-09-16
UA93911C2 (ru) 2011-03-25
ZA200809531B (en) 2010-03-31
CN101374533A (zh) 2009-02-25
BRPI0710944B8 (pt) 2021-05-25
EP2040722A1 (en) 2009-04-01
JP2009539371A (ja) 2009-11-19
JP2013173749A (ja) 2013-09-05
CN102488717B (zh) 2018-03-27
JP5865283B2 (ja) 2016-02-17
US9340840B2 (en) 2016-05-17
HK1125840A1 (en) 2009-08-21
KR101308865B1 (ko) 2013-09-17
CA2650546C (en) 2011-08-02
CN101374533B (zh) 2012-02-01
MX2008014869A (es) 2008-12-05
WO2007142596A1 (en) 2007-12-13
KR20090015903A (ko) 2009-02-12
NZ572359A (en) 2011-12-22
GEP20125480B (en) 2012-04-25
AU2010202976A1 (en) 2010-08-05
CN102488717A (zh) 2012-06-13
BRPI0710944B1 (pt) 2020-12-29
KR101030661B1 (ko) 2011-04-20
AU2010202976B2 (en) 2012-12-20
CA2650546A1 (en) 2007-12-13
AU2007200434B2 (en) 2010-09-02
MY162708A (en) 2017-07-14
KR20100080565A (ko) 2010-07-08
US20080131414A1 (en) 2008-06-05
IL194779A0 (en) 2009-08-03
US20120121564A1 (en) 2012-05-17
US20070280913A1 (en) 2007-12-06
US9057112B2 (en) 2015-06-16

Similar Documents

Publication Publication Date Title
NZ596788A (en) Use of selected lactic acid bacteria for reducing infantile colic
UA101316C2 (ru) Применение отобранных молочнокислых бактерий для профилактики и лечения атеросклероза
PH12014501749B1 (en) A nutritional composition comprising probiotics and improving sleep patterns
MX2009009931A (es) Probioticos para reducir el desarrollo de alergia en lactantes nacidos por cesarea.
EP4560007A3 (en) Compositions for metabolic health
WO2009068214A3 (de) Heteroaryl-substituierte piperidine
MX2009003620A (es) Metodo para obtener variantes de bacterias de acido lactico utilizables para producir vitamina k2 y aplicacion a la preparacion de productos alimenticios.
WO2007025977A8 (en) Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
TNSN08279A1 (en) Bayer healthcare ag
NZ597853A (en) Modified agrin-fragment capable of restoring muscle strength for use as a medicament
NZ595217A (en) Composition for producing a fungicide and a biological bactericide
PL2224820T3 (pl) Produkty żywnościowe
WO2010103548A3 (en) Improved method for producing lactic acid and derivative thereof
UA91541C2 (ru) Бактерицидные макроциклы v, которые содержат амидные группы
IL194353A0 (en) Lysobactin amides
WO2023092141A3 (en) Compositions for metabolic health
TW200621799A (en) Acylated nonadepsipeptides II
ATE455789T1 (de) Substituierte nonadepsipeptide
PL1687014T3 (pl) Zastosowanie dodatkowo przefermentowanego wywaru zbożowego do zapobiegania i/lub leczenia podwyższonych wartości cukru we krwi
AU2003286294A1 (en) Process to improve milk coagulation by means of strains of lactic bacteria, new strains and their use in said process
BG108706U (en) Biologically active lactic acid product
NZ612095A (en) Improved tolerance in a low calorie infant formula
BG108655A (en) Starter culture for probiotic products
HK1125658A (en) Lysobactin amides
NZ594855A (en) Bacteriocins and novel bacterial strains

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 MAY 2014 BY LEA SKYLLERSTEDT

Effective date: 20131009

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 MAY 2017 BY LEA SKYLLERSTEDT

Effective date: 20140520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2018 BY CPA GLOBAL(PATRAFEE)

Effective date: 20170516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20180518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2020 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20190508

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2021 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20200525

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2022 BY CAMILLA WELLIN / CPA GLOBAL

Effective date: 20210504

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE

Effective date: 20220430

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2024 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20230504

LAPS Patent lapsed